Analysts at Wedbush boosted their Q1 2025 EPS estimates for shares of Alphabet in a research report issued on Wednesday, ...

Fintel reports that on February 6, 2025, Wedbush initiated coverage of Bicara Therapeutics (NasdaqGM:BCAX) with a Outperform ...

Adicet Bio (NASDAQ:ACET – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. A number of other ...

Revenue: Analysts tracked by FactSet expect $187.3 billion in revenue, up from $170.0 billion a year before. The FactSet consensus calls for 8.6% growth in North America revenue to $114.6 billion, 9.7 ...

Palantir trades at valuations such that the stock still looks richly valued even after hyperbolic growth in its business.

In a report released today, Jay McCanless from Wedbush maintained a Hold rating on LGI Homes (LGIH – Research Report), with a price target of ...

In a report released today, Robert Driscoll from Wedbush maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target ...

In many ways, these have been tough days for Tesla. Falling sales. Squeezed profit margins. Proposed changes in US government ...

Palantir Technologies shares soared to an all-time high Tuesday after the company's outlook blew past analysts' expectations on strong demand for AI.

Wedbush's Dan Ives believes buying Palantir Technologies Inc (NYSE:PLTR) stock right now could be like buying Tesla Inc ...